← All organizations
Highest phase reached
Phase 3
First clinical trial
Mar 1, 2009Last known activity
Feb 24, 2020
Acquired by Sumitomo Dainippon on Jan 1, 2012
Timeline
2000s
- Jan 1, 2007
Boston Biomedical— Founded
2010s
- Jan 1, 2012
Sumitomo Dainippon— Acquired By
Drugs by trial phase (28 distinct, 30 trials)
Phase 3 (7 own, 0 via acquisition)
Phase 2 (13 own, 0 via acquisition)
Phase 1 (8 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Pancreatic Ductal
- Carcinoma, Renal Cell
- Carcinoma, Transitional Cell
- Cholangiocarcinoma
- Colorectal Neoplasms
- Fallopian Tube Neoplasms
- Gastrointestinal Neoplasms
- Gastrointestinal Stromal Tumors
- Glioblastoma
- Microsatellite Instability
- Myelodysplastic Syndromes
- Neoplasm Metastasis
- Neoplasms
- Ovarian Neoplasms
- Primary Myelofibrosis
- Squamous Cell Carcinoma of Head and Neck
- Stomach Neoplasms
Recent trials (31)
- NCT04299880Lead sponsorPhase 1Feb 24, 2020
- NCT04176198Lead sponsorPhase 1Dec 31, 2019
- NCT03416335Lead sponsorPhase 1Jun 1, 2018
- NCT03525405Lead sponsorPhase 1May 18, 2018
- NCT03416816Lead sponsorPhase 1May 15, 2018
- NCT03311334Lead sponsorPhase 1Dec 14, 2017
- NCT03411122Lead sponsorPhase 1Jun 30, 2017
- NCT03149003Lead sponsorPhase 2Jun 1, 2017
- NCT02232620Lead sponsorPhase 2Mar 13, 2017
- NCT02232646Lead sponsorPhase 2Jan 1, 2017
- NCT02993731Lead sponsorPhase 3Dec 1, 2016
- NCT02826161Lead sponsorPhase 3Nov 1, 2016
- NCT02753127Lead sponsorPhase 3Jun 1, 2016
- NCT02498665Lead sponsorPhase 1Nov 1, 2015
- NCT02483247Lead sponsorPhase 1/Phase 2Sep 1, 2015
Details
- Founded
- Cambridge, MA, US Jan 1, 2007
- Last known activity
- Feb 24, 2020